Last reviewed · How we verify
14^C-labeled ertugliflozin for oral use — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
14^C-labeled ertugliflozin for oral use (14^C-labeled ertugliflozin for oral use) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 14^C-labeled ertugliflozin for oral use TARGET | 14^C-labeled ertugliflozin for oral use | Merck Sharp & Dohme LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 14^C-labeled ertugliflozin for oral use CI watch — RSS
- 14^C-labeled ertugliflozin for oral use CI watch — Atom
- 14^C-labeled ertugliflozin for oral use CI watch — JSON
- 14^C-labeled ertugliflozin for oral use alone — RSS
Cite this brief
Drug Landscape (2026). 14^C-labeled ertugliflozin for oral use — Competitive Intelligence Brief. https://druglandscape.com/ci/14-c-labeled-ertugliflozin-for-oral-use. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab